Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: The TARDIS RCT

Bath, Philip M.; Woodhouse, Lisa J.; Appleton, Jason P.; Beridze, Maia; Christensen, Hanne; Dineen, Robert A.; Flaherty, Katie; Duley, Lelia; England, Timothy J.; Havard, Diane; Heptinstall, Stan; James, Marilyn; Kasonde, Chibeka; Krishnan, Kailash; Markus, Hugh S.; Montgomery, Alan A.; Pocock, Stuart; Randall, Marc; Ranta, Annamarei; Robinson, Thompson G.; Scutt, Polly; Venables, Graham S.; Sprigg, Nikola

doi:10.3310/hta22480

All Outputs (1)

Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: The TARDIS RCT (2018)
Journal Article
Bath, P. M., Woodhouse, L. J., Appleton, J. P., Beridze, M., Christensen, H., Dineen, R. A., …Sprigg, N. (2018). Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: The TARDIS RCT. Health Technology Assessment, 22(48), 1-75. https://doi.org/10.3310/hta22480

© Queen’s Printer and Controller of HMSO 2018. Background: Two antiplatelet agents are better than one for preventing recurrent stroke after acute ischaemic stroke or transient ischaemic attack (TIA). Therefore, intensive treatment with three agents... Read More about Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: The TARDIS RCT.